112 Federal Register / Vol. 86, No. 1 / Monday, January 4, 2021 / Notices 

make an oral comment are required to 

register online at https://

ntp.niehs.nih.gov/go/165 by January 26, 

2021. Oral comments will be received 

only during the formal comment periods 

indicated on the preliminary agenda. 

Oral comments will only be by 

teleconference line. The access number 

for the teleconference line will be 

provided to registrants by email prior to 

the meeting. Registration is on a firstcome, first-served basis. Each 

organization is allowed one time slot 

per topic. After the maximum number of 

speakers per comment period is 

exceeded, individuals registered to 

provide oral comment will be placed on 

a wait list and notified should an 

opening become available. Commenters 

will be notified approximately one week 

before the meeting about the actual time 

allotted per speaker. 

If possible, oral public commenters 

should send a copy of their slides and/ 

or statement or talking points to NTPMeetings@icf.com by January 26, 2021. 

Meeting Materials: The preliminary 

meeting agenda is available on the 

meeting web page (https://

ntp.niehs.nih.gov/go/165) and will be 

updated one week before the meeting. 

Individuals are encouraged to access the 

meeting web page to stay abreast of the 

most current information regarding the 

meeting. 

Background Information on the BSC: 

The BSC is a technical advisory body 

comprised of scientists from the public 

and private sectors that provides 

primary scientific oversight to the NTP. 

Specifically, the BSC advises the NTP 

on matters of scientific program content, 

both present and future, and conducts 

periodic review of the program for the 

purpose of determining and advising on 

the scientific merit of its activities and 

their overall scientific quality. Its 

members are selected from recognized 

authorities knowledgeable in fields such 

as toxicology, pharmacology, pathology, 

epidemiology, risk assessment, 

carcinogenesis, mutagenesis, cellular 

biology, computational toxicology, 

neurotoxicology, genetic toxicology, 

reproductive toxicology or teratology, 

and biostatistics. Members serve 

overlapping terms of up to four years. 

The BSC usually meets periodically. 

The authority for the BSC is provided by 

42 U.S.C. 217a, section 222 of the Public 

Health Service Act (PHS), as amended. 

The BSC is governed by the 

provisions of the Federal Advisory 

Committee Act, as amended (5 U.S.C. 

app.), which sets forth standards for the 

formation and use of advisory 

committees. 

Dated: December 29, 2020. 

Brian R. Berridge, 

Associate Director, National Toxicology 

Program. 

[FR Doc. 2020–29079 Filed 12–31–20; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Substance Abuse and Mental Health 

Services Administration 

Current List of HHS-Certified 

Laboratories and Instrumented Initial 

Testing Facilities Which Meet Minimum 

Standards To Engage in Urine and Oral 

Fluid Drug Testing for Federal 

Agencies 

AGENCY: Substance Abuse and Mental 

Health Services Administration, HHS. 

ACTION: Notice. 

SUMMARY: The Department of Health and 

Human Services (HHS) notifies federal 

agencies of the laboratories and 

Instrumented Initial Testing Facilities 

(IITFs) currently certified to meet the 

standards of the Mandatory Guidelines 

for Federal Workplace Drug Testing 

Programs using Urine or Oral Fluid 

(Mandatory Guidelines). 

FOR FURTHER INFORMATION CONTACT: 

Anastasia Donovan, Division of 

Workplace Programs, SAMHSA/CSAP, 

5600 Fishers Lane, Room 16N06B, 

Rockville, Maryland 20857; 240–276– 

2600 (voice); Anastasia.Donovan@

samhsa.hhs.gov (email). 

SUPPLEMENTARY INFORMATION: A notice 

listing all currently HHS-certified 

laboratories and IITFs is published in 

the Federal Register during the first 

week of each month. If any laboratory or 

IITF certification is suspended or 

revoked, the laboratory or IITF will be 

omitted from subsequent lists until such 

time as it is restored to full certification 

under the Mandatory Guidelines. 

If any laboratory or IITF has 

withdrawn from the HHS National 

Laboratory Certification Program (NLCP) 

during the past month, it will be listed 

at the end and will be omitted from the 

monthly listing thereafter. 

This notice is also available on the 

internet at https://www.samhsa.gov/ 

workplace/resources/drug-testing/ 

certified-lab-list. 

The Department of Health and Human 

Services (HHS) notifies federal agencies 

of the laboratories and Instrumented 

Initial Testing Facilities (IITFs) 

currently certified to meet the standards 

of the Mandatory Guidelines for Federal 

Workplace Drug Testing Programs 

(Mandatory Guidelines) using Urine and 

of the laboratories currently certified to 

meet the standards of the Mandatory 

Guidelines using Oral Fluid. 

The Mandatory Guidelines using 

Urine were first published in the 

Federal Register on April 11, 1988 (53 

FR 11970), and subsequently revised in 

the Federal Register on June 9, 1994 (59 

FR 29908); September 30, 1997 (62 FR 

51118); April 13, 2004 (69 FR 19644); 

November 25, 2008 (73 FR 71858); 

December 10, 2008 (73 FR 75122); April 

30, 2010 (75 FR 22809); and on January 

23, 2017 (82 FR 7920). 

The Mandatory Guidelines using Oral 

Fluid were first published in the 

Federal Register on October 25, 2019 

(84 FR 57554) with an effective date of 

January 1, 2020. 

The Mandatory Guidelines were 

initially developed in accordance with 

Executive Order 12564 and section 503 

of Public Law 100–71 and allowed urine 

drug testing only. The Mandatory 

Guidelines using Urine have since been 

revised, and new Mandatory Guidelines 

allowing for oral fluid drug testing have 

been published. The Mandatory 

Guidelines require strict standards that 

laboratories and IITFs must meet in 

order to conduct drug and specimen 

validity tests on specimens for federal 

agencies. HHS does not allow IITFs to 

conduct oral fluid testing. 

To become certified, an applicant 

laboratory or IITF must undergo three 

rounds of performance testing plus an 

on-site inspection. To maintain that 

certification, a laboratory or IITF must 

participate in a quarterly performance 

testing program plus undergo periodic, 

on-site inspections. 

Laboratories and IITFs in the 

applicant stage of certification are not to 

be considered as meeting the minimum 

requirements described in the HHS 

Mandatory Guidelines using Urine and/ 

or Oral Fluid. An HHS-certified 

laboratory or IITF must have its letter of 

certification from HHS/SAMHSA 

(formerly: HHS/NIDA), which attests 

that the test facility has met minimum 

standards. HHS does not allow IITFs to 

conduct oral fluid testing. 

HHS-Certified Laboratories Approved 

To Conduct Oral Fluid Drug Testing 

In accordance with the Mandatory 

Guidelines using Oral Fluid dated 

October 25, 2019 (84 FR 57554), the 

following HHS-certified laboratories 

meet the minimum standards to conduct 

drug and specimen validity tests on oral 

fluid specimens: 

At this time, there are no laboratories 

certified to conduct drug and specimen 

validity tests on oral fluid specimens. 

Federal Register / Vol. 86, No. 1 / Monday, January 4, 2021 / Notices 113 

* The Standards Council of Canada (SCC) voted 

to end its Laboratory Accreditation Program for 

Substance Abuse (LAPSA) effective May 12, 1998. 

Laboratories certified through that program were 

accredited to conduct forensic urine drug testing as 

required by U.S. Department of Transportation 

(DOT) regulations. As of that date, the certification 

of those accredited Canadian laboratories will 

continue under DOT authority. The responsibility 

for conducting quarterly performance testing plus 

periodic on-site inspections of those LAPSAaccredited laboratories was transferred to the U.S. 

HHS, with the HHS’ NLCP contractor continuing to 

have an active role in the performance testing and 

laboratory inspection processes. Other Canadian 

laboratories wishing to be considered for the NLCP 

may apply directly to the NLCP contractor just as 

U.S. laboratories do. 

Upon finding a Canadian laboratory to be 

qualified, HHS will recommend that DOT certify 

the laboratory (Federal Register, July 16, 1996) as 

meeting the minimum standards of the Mandatory 

Guidelines published in the Federal Register on 

January 23, 2017 (82 FR 7920). After receiving DOT 

certification, the laboratory will be included in the 

monthly list of HHS-certified laboratories and 

participate in the NLCP certification maintenance 

program. 

HHS-Certified Instrumented Initial 

Testing Facilities Approved To Conduct 

Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified IITFs meet the minimum 

standards to conduct drug and specimen 

validity tests on urine specimens: 

Dynacare, 6628 50th Street NW, 

Edmonton, AB Canada T6B 2N7, 780– 

784–1190. (Formerly: GammaDynacare Medical Laboratories) 

HHS-Certified Laboratories Approved 

To Conduct Urine Drug Testing 

In accordance with the Mandatory 

Guidelines using Urine dated January 

23, 2017 (82 FR 7920), the following 

HHS-certified laboratories meet the 

minimum standards to conduct drug 

and specimen validity tests on urine 

specimens: 

Alere Toxicology Services, 1111 Newton 

St., Gretna, LA 70053, 504–361–8989/ 

800–433–3823. (Formerly: Kroll 

Laboratory Specialists, Inc., 

Laboratory Specialists, Inc.) 

Alere Toxicology Services, 450 

Southlake Blvd., Richmond, VA 

23236, 804–378–9130. (Formerly: 

Kroll Laboratory Specialists, Inc., 

Scientific Testing Laboratories, Inc.; 

Kroll Scientific Testing Laboratories, 

Inc.) 

Clinical Reference Laboratory, Inc., 8433 

Quivira Road, Lenexa, KS 66215– 

2802, 800–445–6917 

Cordant Health Solutions, 2617 East L 

Street, Tacoma, WA 98421, 800–442– 

0438. (Formerly: STERLING Reference 

Laboratories) 

Desert Tox, LLC, 5425 E Bell Rd., Suite 

125, Scottsdale, AZ, 85254, 602–457– 

5411/623–748–5045 

DrugScan, Inc., 200 Precision Road, 

Suite 200, Horsham, PA 19044, 800– 

235–4890 

Dynacare,* 245 Pall Mall Street, 

London, ONT, Canada N6A 1P4, 519– 

679–1630. (Formerly: GammaDynacare Medical Laboratories) 

ElSohly Laboratories, Inc., 5 Industrial 

Park Drive, Oxford, MS 38655, 662– 

236–2609 

Laboratory Corporation of America 

Holdings, 7207 N Gessner Road, 

Houston, TX 77040, 713–856–8288/ 

800–800–2387 

Laboratory Corporation of America 

Holdings, 69 First Ave., Raritan, NJ 

08869, 908–526–2400/800–437–4986. 

(Formerly: Roche Biomedical 

Laboratories, Inc.) 

Laboratory Corporation of America 

Holdings, 1904 TW Alexander Drive, 

Research Triangle Park, NC 27709, 

919–572–6900/800–833–3984. 

(Formerly: LabCorp Occupational 

Testing Services, Inc., CompuChem 

Laboratories, Inc.; CompuChem 

Laboratories, Inc., A Subsidiary of 

Roche Biomedical Laboratory; Roche 

CompuChem Laboratories, Inc., A 

Member of the Roche Group) 

Laboratory Corporation of America 

Holdings, 1120 Main Street, 

Southaven, MS 38671, 866–827–8042/ 

800–233–6339. (Formerly: LabCorp 

Occupational Testing Services, Inc.; 

MedExpress/National Laboratory 

Center) 

LabOne, Inc. d/b/a Quest Diagnostics, 

10101 Renner Blvd., Lenexa, KS 

66219, 913–888–3927/800–873–8845. 

(Formerly: Quest Diagnostics 

Incorporated; LabOne, Inc.; Center for 

Laboratory Services, a Division of 

LabOne, Inc.) 

Legacy Laboratory Services Toxicology, 

1225 NE 2nd Ave., Portland, OR 

97232, 503–413–5295/800–950–5295 

MedTox Laboratories, Inc., 402 W 

County Road D, St. Paul, MN 55112, 

651–636–7466/800–832–3244 

Minneapolis Veterans Affairs Medical 

Center, Forensic Toxicology 

Laboratory, 1 Veterans Drive, 

Minneapolis, MN 55417, 612–725– 

2088. Testing for Veterans Affairs 

(VA) Employees Only 

Pacific Toxicology Laboratories, 9348 

DeSoto Ave., Chatsworth, CA 91311, 

800–328–6942. (Formerly: Centinela 

Hospital Airport Toxicology 

Laboratory) 

Phamatech, Inc., 15175 Innovation 

Drive, San Diego, CA 92128, 888– 

635–5840 

Quest Diagnostics Incorporated, 1777 

Montreal Circle, Tucker, GA 30084, 

800–729–6432. (Formerly: SmithKline 

Beecham Clinical Laboratories; 

SmithKline Bio-Science Laboratories) 

Quest Diagnostics Incorporated, 400 

Egypt Road, Norristown, PA 19403, 

610–631–4600/877–642–2216. 

(Formerly: SmithKline Beecham 

Clinical Laboratories; SmithKline BioScience Laboratories) 

Redwood Toxicology Laboratory, 3700 

Westwind Blvd., Santa Rosa, CA 

95403, 800–255–2159 

US Army Forensic Toxicology Drug 

Testing Laboratory, 2490 Wilson St., 

Fort George G. Meade, MD 20755– 

5235, 301–677–7085. Testing for 

Department of Defense (DoD) 

Employees Only 

Anastasia Marie Donovan, 

Policy Analyst. 

[FR Doc. 2020–29059 Filed 12–31–20; 8:45 am] 

BILLING CODE 4160–20–P 

DEPARTMENT OF HOMELAND 

SECURITY 

Federal Emergency Management 

Agency 

[Docket ID: FEMA–2020–0040; OMB No. 

1660–0150] 

Agency Information Collection 

Activities: Proposed Collection; 

Comment Request; Rated Orders, 

Adjustments, Exceptions, or Appeals 

Under the Emergency Management 

Priorities and Allocations System 

(EMPAS) 

AGENCY: Federal Emergency 

Management Agency, DHS. 

ACTION: 60-Day notice and request for 

comments. 

SUMMARY: The Federal Emergency 

Management Agency, as part of its 

continuing effort to reduce paperwork 

and respondent burden, invites the 

general public to take this opportunity 

to comment on a revision of a currently 

approved information collection. In 

accordance with the Paperwork 

Reduction Act of 1995, this notice seeks 

comments concerning information 

necessary to support the President’s 

priorities and allocations authority 

under the DPA implemented by the 

Emergency Management Priorities and 

Allocations System (EMPAS) regulation, 

which was added by FEMA’s May 13, 

2020, Emergency Management Priorities 

and Allocations System Interim Final 

Rule. 

DATES: Comments must be submitted on 

or before March 5, 2021. 

ADDRESSES: Submit comments at 

www.regulations.gov under Docket ID